African Programme for Onchocerciasis Control, WHO/APOC P, O, Box: 01 B,P, 549, Ouagadougou 01, Burkina Faso.
Parasit Vectors. 2012 Feb 7;5:28. doi: 10.1186/1756-3305-5-28.
Onchocerciasis can be effectively controlled as a public health problem by annual mass drug administration of ivermectin, but it was not known if ivermectin treatment in the long term would be able to achieve elimination of onchocerciasis infection and interruption of transmission in endemic areas in Africa. A recent study in Mali and Senegal has provided the first evidence of elimination after 15-17 years of treatment. Following this finding, the African Programme for Onchocerciasis Control (APOC) has started a systematic evaluation of the long-term impact of ivermectin treatment projects and the feasibility of elimination in APOC supported countries. This paper reports the first results for two onchocerciasis foci in Kaduna, Nigeria.
In 2008, an epidemiological evaluation using skin snip parasitological diagnostic method was carried out in two onchocerciasis foci, in Birnin Gwari Local Government Area (LGA), and in the Kauru and Lere LGAs of Kaduna State, Nigeria. The survey was undertaken in 26 villages and examined 3,703 people above the age of one year. The result was compared with the baseline survey undertaken in 1987.
The communities had received 15 to 17 years of ivermectin treatment with more than 75% reported coverage. For each surveyed community, comparable baseline data were available. Before treatment, the community prevalence of O. volvulus microfilaria in the skin ranged from 23.1% to 84.9%, with a median prevalence of 52.0%. After 15 to 17 years of treatment, the prevalence had fallen to 0% in all communities and all 3,703 examined individuals were skin snip negative.
The results of the surveys confirm the finding in Senegal and Mali that ivermectin treatment alone can eliminate onchocerciasis infection and probably disease transmission in endemic foci in Africa. It is the first of such evidence for the APOC operational area.
通过每年大规模给予伊维菌素进行药物治疗,盘尾丝虫病可以得到有效控制,成为一个公共卫生问题。但尚不清楚伊维菌素长期治疗是否能够在非洲流行地区实现消除盘尾丝虫病感染和阻断传播。最近在马里和塞内加尔进行的一项研究提供了治疗 15-17 年后消除的首个证据。在这一发现之后,非洲盘尾丝虫病控制规划(APOC)开始对伊维菌素治疗项目的长期影响以及在 APOC 支持的国家消除盘尾丝虫病的可行性进行系统评估。本文报告了尼日利亚卡杜纳两个盘尾丝虫病流行区的初步结果。
2008 年,在尼日利亚卡杜纳州 Birnin Gwari 地方政府区(LGA)和 Kauru 和 Lere LGA 两个盘尾丝虫病流行区,采用皮肤划痕寄生虫学诊断方法进行了流行病学评估。该调查在 26 个村庄进行,检查了 3703 名 1 岁以上的人。结果与 1987 年进行的基线调查进行了比较。
这些社区已经接受了 15 至 17 年的伊维菌素治疗,报告的覆盖率超过 75%。对于每个接受调查的社区,都有可比的基线数据。在治疗前,皮肤中 O. volvulus 微丝蚴的社区流行率在 23.1%至 84.9%之间,中位数为 52.0%。经过 15 至 17 年的治疗后,所有社区的流行率均降至 0%,所有 3703 名接受检查的人皮肤划痕均为阴性。
调查结果证实了在塞内加尔和马里的发现,即单独使用伊维菌素治疗可以消除非洲流行区的盘尾丝虫病感染,可能还可以消除疾病传播。这是 APOC 行动区的首例此类证据。